Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872922 | 0.90 | MAPT (0.41) | MAPTMEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL5872769 | 0.89 | SLC6A9 (0.39) | MAPTMEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL5872904 | 0.81 | MAP2K1 (0.42) | MAPTMEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL5872773 | 0.80 | NAAA (0.40) | MAPTMEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL5872805 | 0.80 | ALDH1A1 (0.51) | MAPTMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL5872899 | 0.80 | NPSR1 (0.39) | MAPTMEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL5872799 | 0.79 | MAP2K1 (0.49) | MEN1KMT2ATDP1MAP2K2MAP2K1 | |
| SCHEMBL5872758 | 0.79 | MAP2K1 (0.47) | MEN1KMT2ATDP1MAP2K2MAP2K1 | |
| SCHEMBL5872869 | 0.78 | MAP2K2 (0.41) | MAPTMEN1KMT2ATDP1MAP2K2 | |
| SCHEMBL5872893 | 0.78 | KMT2A (0.40) | MAPTMEN1KMT2ATDP1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001905-B2 | Substituted diarylamines as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | BIWERSI CATHLIN (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | NRAS, MAPK6, MAPK12 | MAPT 4808/4885MEN1 2841/4885KMT2A 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.